These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16344384)

  • 41. [The effect of paclitaxel-eluting stents on restenosis].
    Kurşaklioğlu H; Köz C; Iyisoy A; Ide T; Yildirim V; Töre HF; Işik E; Demirtaş E
    Anadolu Kardiyol Derg; 2006 Mar; 6(1):18-23. PubMed ID: 16524795
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions.
    Grube E; Dawkins KD; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Buellesfeld L; Koglin J; Russell ME
    Eur Heart J; 2007 Nov; 28(21):2578-82. PubMed ID: 17938126
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study.
    Takagi T; Akasaka T; Yamamuro A; Honda Y; Hozumi T; Morioka S; Yoshida K
    J Am Coll Cardiol; 2000 Nov; 36(5):1529-35. PubMed ID: 11079654
    [TBL] [Abstract][Full Text] [Related]  

  • 44. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.
    Stone GW; Ellis SG; Cox DA; Hermiller J; O'Shaughnessy C; Mann JT; Turco M; Caputo R; Bergin P; Greenberg J; Popma JJ; Russell ME;
    Circulation; 2004 Apr; 109(16):1942-7. PubMed ID: 15078803
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 7-hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE).
    Kataoka T; Grube E; Honda Y; Morino Y; Hur SH; Bonneau HN; Colombo A; Di Mario C; Guagliumi G; Hauptmann KE; Pitney MR; Lansky AJ; Stertzer SH; Yock PG; Fitzgerald PJ
    Circulation; 2002 Oct; 106(14):1788-93. PubMed ID: 12356631
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Polymer-based paclitaxel-eluting stents are superior to nonpolymer-based paclitaxel-eluting stents in the treatment of de novo coronary lesions.
    Iofina E; Langenberg R; Blindt R; Kühl H; Kelm M; Hoffmann R
    Am J Cardiol; 2006 Oct; 98(8):1022-7. PubMed ID: 17027564
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model.
    Tada N; Virmani R; Grant G; Bartlett L; Black A; Clavijo C; Christians U; Betts R; Savage D; Su SH; Shulze J; Kar S
    Circ Cardiovasc Interv; 2010 Apr; 3(2):174-83. PubMed ID: 20407114
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influence of plaque calcium on neointimal hyperplasia following bare metal and drug-eluting stent implantation.
    Shimada Y; Kataoka T; Courtney BK; Morino Y; Bonneau HN; Yock PG; Grube E; Honda Y; Fitzgerald PJ
    Catheter Cardiovasc Interv; 2006 Jun; 67(6):866-9. PubMed ID: 16649232
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients.
    Aoki J; Abizaid AC; Serruys PW; Ong AT; Boersma E; Sousa JE; Bruining N
    J Am Coll Cardiol; 2005 Nov; 46(9):1670-6. PubMed ID: 16256867
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravascular ultrasound assessment of neointima distribution and the length of stent that was free of intravascular ultrasound-detectable intimal hyperplasia in paclitaxel-eluting stents.
    Mintz GS; Hong MK; Raizner AE; Lee CW; Kim JJ; Escolar E; Fearnot NE; Park SW; Park SJ; Weissman NJ
    Am J Cardiol; 2005 Jan; 95(1):107-9. PubMed ID: 15619404
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term evaluation of paclitaxel-coated stents for treatment of native coronary lesions. First results of both the clinical and angiographic 18 month follow-up of TAXUS I.
    Büllesfeld L; Gerckens U; Müller R; Grube E
    Z Kardiol; 2003 Oct; 92(10):825-32. PubMed ID: 14579046
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term vessel response to a self-expanding coronary stent: a serial volumetric intravascular ultrasound analysis from the ASSURE Trial.A Stent vs. Stent Ultrasound Remodeling Evaluation.
    Kobayashi Y; Honda Y; Christie GL; Teirstein PS; Bailey SR; Brown CL; Matthews RV; De Franco AC; Schwartz RS; Goldberg S; Popma JJ; Yock PG; Fitzgerald PJ
    J Am Coll Cardiol; 2001 Apr; 37(5):1329-34. PubMed ID: 11300443
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery.
    Dangas G; Ellis SG; Shlofmitz R; Katz S; Fish D; Martin S; Mehran R; Russell ME; Stone GW;
    J Am Coll Cardiol; 2005 Apr; 45(8):1186-92. PubMed ID: 15837247
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A paclitaxel-eluting stent for the prevention of coronary restenosis.
    Park SJ; Shim WH; Ho DS; Raizner AE; Park SW; Hong MK; Lee CW; Choi D; Jang Y; Lam R; Weissman NJ; Mintz GS
    N Engl J Med; 2003 Apr; 348(16):1537-45. PubMed ID: 12700373
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries.
    Speck U; Scheller B; Abramjuk C; Breitwieser C; Dobberstein J; Boehm M; Hamm B
    Radiology; 2006 Aug; 240(2):411-8. PubMed ID: 16864669
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer.
    Grube E; Sonoda S; Ikeno F; Honda Y; Kar S; Chan C; Gerckens U; Lansky AJ; Fitzgerald PJ
    Circulation; 2004 May; 109(18):2168-71. PubMed ID: 15123533
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relation of intimal hyperplasia thickness to stent size in paclitaxel-coated stents.
    Escolar E; Mintz GS; Hong MK; Lee CW; Kim JJ; Fearnot NE; Park SW; Park SJ; Weissman NJ
    Am J Cardiol; 2004 Jul; 94(2):196-8. PubMed ID: 15246900
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.
    Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Bruining N; Van den Branden F; Van Langenhove G
    J Am Coll Cardiol; 2006 Dec; 48(12):2423-31. PubMed ID: 17174178
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation.
    Cook S; Wenaweser P; Togni M; Billinger M; Morger C; Seiler C; Vogel R; Hess O; Meier B; Windecker S
    Circulation; 2007 May; 115(18):2426-34. PubMed ID: 17485593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.